

PATHEON INC
Form 8-K/A
January 11, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2012

PATHEON INC.

(Exact name of registrant as specified in its charter)

Edgar Filing: PATHEON INC - Form 8-K/A

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

c/o Patheon Pharmaceuticals Services Inc.

4721 Emperor Boulevard, Suite 200

Durham, NC
(Address of principal executive offices)

Registrant's telephone number, including area code: (919) 226-3200

27703
(Zip Code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

EXPLANATORY NOTE

This Amendment No. 1 on Form 8-K/A (the Amended Form 8-K) for Patheon Inc. (the Company) amends the Current Report on Form 8-K originally filed with the Securities and Exchange Commission on August 13, 2012 disclosing the separation from the Company of Mark J. Kontny, Ph.D. (the Original Form 8-K). This Amended Form 8-K is being filed to disclose the entry by Dr. Kontny and the Company into the Agreement (as defined below). Except for the disclosures related to the Agreement, the disclosures made in this Amended Form 8-K are as of August 13, 2012, the date of the Original Form 8-K, and have not been amended, updated or otherwise modified.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 13, 2012, Patheon Inc. (the Company) announced that Mark J. Kontny, Ph.D., President, Global Pharmaceutical Development Services and Chief Scientific Officer, is no longer employed by the Company, effective as of this date.

A copy of the press release announcing Dr. Kontny s separation is attached hereto as Exhibit 99.1.

On January 8, 2013, Patheon Pharmaceuticals Services Inc., an indirect wholly owned subsidiary of the Company, and Dr. Kontny entered into a Severance and Release of Claims Agreement (the Agreement). Pursuant to the Agreement, Dr. Kontny will receive a total of \$520,000, payable in 12 equal monthly installments, in exchange for providing the Company and its affiliates a customary release of claims and agreeing to abide by customary confidentiality, nondisparagement and cooperation provisions.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 11, 2013

PATHEON INC.

By: /s/ Stuart Grant
Stuart Grant
Executive Vice President, Chief Financial Officer

: solid black; border-top-width: 1; border-left-width: 1; border-right-width: 1; border-bottom-width: 1">**Reporting**
Owner Name / AddressRelationships Director 10% Owner Officer Other**DENSON CHARLES D**
ONE BOWERMAN DRIVE
BEAVERTON, OR 97005 President-NIKE Brand

Signatures

By: John F. Coburn III For: Charles
Denson 02/19/2008

__Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Pursuant to Company policy, market sales of Company stock by officers and directors are permitted only after the second full trading day
- (1) after the release of quarterly earnings and ending on the last day of the second month of the following fiscal quarter, except pursuant to approved 10b5-1 trading plans.
- (2) Includes 31,045 restricted shares granted under the NIKE, Inc. 1990 Stock Incentive Plan.
- (3) Shares held in account under NIKE, Inc. Employee Stock Purchase Plan.
- (4) Shares held in account under the NIKE, Inc. 401(K) and Profit Sharing Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.